Your Messages Inbox
Your Article Summary
See Latest Articles(Click the title below to leave the MDLinx Network and go to the Journal's Website)
Merck Discontinues Development of Investigational Medicine Taranabant for Obesity
Merck & Co., 10/06/08
Merck & Co., Inc. will not seek regulatory approval for taranabant, an investigational medicine, to treat obesity and is discontinuing its Phase III clinical development program for taranabant for obesity.
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects
b3c newswire, 12/07/09
Allos Therapeutics Reports New Analyses of Data from Pivotal PROPEL Trial of FOLOTYN at 51st ASH Annual Meeting
Allos Therapeutics, 12/07/09
Nplate Data From MDS Studies Presented at ASH
Amgen, 12/07/09
Article Search
Sponsor